Neil S. Belloff - 25 May 2021 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc.

Role: COO, GENERAL COUNSEL &CORP SEC
Signature: /s/ Neil S. Belloff
Issuer symbol: N/A
Transactions as of: 25 May 2021
Net transactions value: -$2,551
Form type: 4
Filing time: 26 May 2021, 16:10:14 UTC
Next filing: 30 Jul 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ELOX	Common Stock	Options Exercise	$0	+6,250	+23%	$0.000000	33,430	25 May 2021	Direct	F1
transaction	ELOX	Common Stock	Tax liability	$2,551	-1,835	-5.5%	$1.39	31,595	25 May 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELOX	Restricted Stock Units	Options Exercise	$0	-6,250	-8.3%	$0.000000	68,750	25 May 2021	Common Stock	6,250		Direct	F1, F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The restricted stock units issued to the reporting person on February 25, 2020 have partially vested and settled for shares of the Issuer's common stock.
F2	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3	The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan.
F4	The remaining restricted stock units will vest ratably each quarter through February 25, 2024, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances.